Actively Recruiting
Phase 1 Study of ADX-626 in Healthy Participants
Led by ADARx Pharmaceuticals, Inc. · Updated on 2026-03-02
44
Participants Needed
1
Research Sites
75 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).
CONDITIONS
Official Title
Phase 1 Study of ADX-626 in Healthy Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 45 years at the time of informed consent
- Male or woman of non-childbearing potential
- Willing to comply with all study requirements during participation
- Suitable venous access for blood sampling
- Body weight at least 50 kg and body mass index 25 kg/m2 or less
- Normal lab results including liver enzymes, hemoglobin, platelet count, and coagulation parameters
- Willing to use acceptable contraception methods if applicable
You will not qualify if you...
- Significant medical condition such as hypertension, diabetes, cardiovascular disease, or cancer
- History of bleeding or coagulation disorders, prior major bleeding events, or family history of bleeding disorders
- Current infection
- Participation in an interventional drug study within the last 90 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Richmond Pharmacology
London, United Kingdom, SE1 1YR
Actively Recruiting
Research Team
N
Nali Castillo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here